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1Chapter
Role of Radiotherapy in High 
Grade Glioma
Henrique Balloni
Abstract
The aim of this review is to explore the changing utility of radiotherapy in the 
treatment of patients with glioblastoma over the past decades. Surgery and radio-
therapy has always been the cornerstone of treatment of glioblastoma, but tech-
niques have significantly advanced over this time. We selected the main studies that 
support the advances of radiotherapy in the present day as well as controversies in 
several aspects of the treatment will be approached; definition of the target volume 
in the magnetic resonance imaging (MRI) planning, size of the margins around 
the target volume; prescribed dose (satnadard vs. hypofactionated); management 
of glioblastoma in elderly; review role of radiosurgery past and new potential 
use in recurrence and the evidence of reirradiation in patients with local recur-
rence. Finally, continued development on many fronts have allowed for modestly 
improved outcomes while at the same time limiting toxicity.
Keywords: glioblastoma, radiotherapy, target volume, hypofractionated, 
radiosurgery
1. Introduction
The benefit of radiation therapy in patients with newly diagnosed glioblastoma 
has been demonstrated in many randomized trials and has been the basis of treat-
ment for decades. To make an effort to achieve and improve the very poor outcomes 
associated with this disease, numerous therapeutics have been added to radiation 
though with lack of success until the landmark study by Stupp et al. [1] established 
a standard of care of treatment, gross surgical excision followed by concurrent 
temozolomide and radiation.
The use of radiation in glioblastoma is constantly evolving as a result of advances 
in imaging methods and personalized medicine leading to continuous controversies 
over the delineations of tumor volume.
Multiple recent studies on personalized medicine, especially in elderly patients 
with glioblastoma suggest that the role and dose/fractionation of radiation delivery 
to this increasing population will continue to develop. This chapter will highlight 
the major historical studies that have resulted in radiation being the current stan-
dard of care; discuss the continuing controversies of volume delineation in radia-
tion delivery planning; discuss dose evolution and fractionation of radiotherapy in 
the management of patients; and review studies and ongoing trials on the use of 
radiation in the salvage scenario.
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2. Radiotherapy target volume definitions
In the 1970s, a randomized trial showed that 60 Gy of postoperative whole-brain 
RT (WBRT) could improve the survival for patients with high-grade glioma (HGG). 
Since then, postoperative RT was a standard treatment for newly diagnosed HGG. [2] 
However, other studies started to compare WBRT with partial-brain irradiation and 
concluded that there was no advantage of WBRT [3]. Tomography (CT) and magnetic 
resonance imaging (MRI) has contributed largely to improve the accuracy of tumor 
delineation and establish that partial-brain irradiation standard to treat HGG [4]. The 
three-dimensional (3D) conformal radiation technique makes partial-brain irradiation 
for glioma possible and reduces neurotoxicity [5]. The image fusion pre- and postopera-
tive MRI with planning CT images is normally used to determine the RT treatment 
volume for GBM. However, the optimal treatment volume for GBM remains a contro-
versial issue and varies among different institutions. The Radiation Therapy Oncology 
Group (RTOG) refers to a two-phase treatment at 60 Gy, where the initial clinical target 
volume (CTV) typically includes postoperative peritumoral edema plus a 2 cm margin, 
followed by a boost field defined as the residual tumor plus a 2 cm margin (as per RTOG 
0525 and RTOG 0825 trials) [6]. Inversely, the European Organization for Research and 
Treatment of Cancer (EORTC) defines a single-phase treatment with 2–3 cm dosimetric 
margins around the tumor (as evaluated by MRI), because 80–90% of treatment failures 
occur within this margin [1]. The University of Texas MD Anderson Cancer Center uses a 
2 cm margin around the gross tumor volume (GTV), which consists of the resection cav-
ity and any residual contrast-enhancing tumor without regard to edema [7]. However, 
several studies have raised the hypothesis that the results are similar when using reduced 
margins as small as 5 mm to delineate the CTV in the treatment of GBM [8].
In daily clinical practice between different institutions, the margins of the planned 
target volume vary significantly. A survey of radiation oncologists in Canada showed 
that 32 and 14% followed the RTOG and EORTC guidelines, respectively, while 54% 
followed the center’s specific guidelines. Biphasic treatments were reported by 37% 
and single-phase by 60% of clinicians. For clinicians treating in single phase, 61% treat 
the surgical cavity and enhancing tumor with a margin, and 33% treat an area that 
includes tumor edema in addition to the surgical cavity and enhancing tumor. The 
GTV margins to generate the planning treatment volume (PTV) also varied widely 
and included 0.5 cm (6%), 1 cm (6%), 1.5 cm (25%), 2 cm (56%), 2.5 cm (25%), and 
3 cm (12.5%). For clinicians treating in multiple phases, 90% include peritumoral 
edema in Phase I of the treatment. In Phase II, respondents reported using total mar-
gins (from GTV to PTV) of 1 cm (10%), 2 cm (40%), 2.5 cm (30%), and 3 cm (20%) 
[9]. Examples of differences in guidelines are shown (Table 1 and Figures 1 and 2).
2.1 Peritumoral edema
It is discussed regarding the inclusion of edema in the treatment plan. The 
rationale for including peritumoral edema is that such areas are believed to contain 
high concentrations of tumor cells. A study compared the histopathologic distri-
butions of neoplastic cells in GBM with the corresponding CT images and found 
that the vast majority of the neoplastic tissue was contained within the contrast-
enhancing and low-density peritumoral areas; however, the CT low-density area 
was not always identical to the area infiltrated by tumor cells. No tumor cells were 
found in some areas of low density, whereas, in some instances, normal appearing 
brain tissue beyond the CT low-density area was also found to contain tumor cells 
[10]. Furthermore, Halperin et al. [11] compared preoperative CT scans with the 
postmortem topography of recurrent tumors and found that 9/11 (81.8%) tumor 
cells were found beyond the enhancement area plus a 1 cm margin on CT. Indeed, 
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only treatment plans that covered the contrast-enhancing tumor, the “edema” 
volume, plus an additional 3 cm margin would cover the entire histologically identi-
fied tumor. Kelly et al. [12] also reported on the correlation between histopathologic 
and MRI findings for 177 biopsy specimens from 39 patients with glial neoplasms. 
Pathologic evaluation of biopsy specimens obtained from various locations in 
the volumes defined by CT and MRI showed that contrast enhancement most 
Table 1. 
The definition of radiation treatment volumes during the delineation of high-grade gliomas.
Figure 1. 
Example planning treatment volumes (PTV) delineation of high grade. MRI T1 contrast enhanced showing in 
colors lines different protocol volumes.
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often corresponded to tumor tissue without intervening parenchyma, whereas 
hypodensity corresponded to parenchyma infiltrated by isolated tumor cells or, in 
some instances, in low-HGGs, to tumor tissue or to edema. For the normal T1- and 
T2-weighted MRI regions that were biopsied, there was a false-negative rate of 69 
and 40%, respectively [13]. A study conducted by Lu et al. [13] analyzed peritumoral 
edema using diffusion tensor MR imaging. This group divided gliomas associated 
with peritumoral edema into tumor-infiltrated edema and purely vasogenic edema.
It is controversial the prognostic of peritumoral edema. Some authors considered 
peritumoral edema on a preoperative MRI to be an independent prognostic fac-
tor, in addition to the postoperative Karnofsky performance score (KPS), age, and 
type of tumor resection [14]. Patients with major edema (>1 cm) had a significant 
shorter overall survival (OS) time, compared to patients with minor edema (<1 cm). 
Another study established that peritumoral edema, noncontrast-enhancing tumor, 
satellites, and multifocality were independent prognostic factors for survival in 
GBM, whereas preoperative tumor size, tumor location, and extent of necrosis had 
no significant impact on survival [15]. Conversely, there was no correlation between 
peritumoral edema, patient age, and tumor volume, but there was an association 
between edema, tumor location, and necrosis [16]. Similarly, Ramakrishna et al. 
[17] analyzed the predictive value of abnormal MRI features for the survival of 
patients with GBM. The result demonstrated that tumor burden and invasion char-
acteristics indicated by the T1-weighted gadolinium-enhanced MRI were significant 
predictors of patient survival, but the total area of signal intensity abnormalities on 
the T2-weighted images and the T2/T1 ratio did not correlate with patient outcome.
In summary, for patients with GBM, the significance of peritumoral edema for the 
survival of a patient with GBM is not clear. A majority of tumor tissues are contained 
Figure 2. 
Example planning treatment volumes (PTV) delineation of high grade. MRI T2 showing in colors lines 
different protocols volumes
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within the contrast enhancement areas in T1-weighted MRI, but not always, and infil-
trate into the peritumoral edema area. We believe that GTV in HGG for RT should be 
focus in T1-weighted MRI and surgical bed, regarding the peritumoral edema area. In 
addition, the ability to accurately distinguish tumor-infiltrated edema from vasogenic 
edema composed purely of extracellular water could be helpful for target delineation. 
It is hoped that advances in image techniques will enable this in the future.
2.2 Recurrent patterns of postoperative GBM
Several studies have studied the pattern of relapse in patients with glioblastoma. 
One of them [18] retrospectively analyzed the patterns of radiographic presentation 
of 80 adult patients with supratentorial GBM at four clinically relevant time points: 
presentation, first recurrence, second recurrence, and third recurrence. At diagno-
sis, 87.5% (70/80), 6.25% (5/80), 3.75%, and 2.5% of patients presented with unifo-
cal disease and distant, multifocal, and diffuse MRI-defined radiographic patterns, 
respectively. After RT and temozolamide treatment local recurrence occurs in 80%, 
distant in 7,5% and multifocal in 6,25% (including one with cerebrospinal fluid 
dissemination), and 6.25% was diffuse. In the same way, Wallner et al. [19] found 
that 78% of unifocal anaplastic astrocytoma and GBM recurrences occurred within 
2 cm of the presurgical original tumor extent, which is defined as the enhancing 
edge of the tumor on preoperative CT, and 56% (18/32) of tumors recurred within 
1 cm of the initial tumor margin. Liang et al. [20] published the pattern of failure 
for 42 patients with grade III or IV astrocytoma treated with chemoradiotherapy 
to a total of 60 Gy. In all 42 patients, recurrence occurred within a 2 cm margin of 
the original CT-enhancing lesion, and 10% of the patients suffered from multifo-
cal recurrence. In a retrospective series of 34 patients treated either with WBRT 
and conformal boost or entirely with 3D conformal RT, Oppitz et al. [21] revealed 
that all GBM recurrences occurred within the 90% isodose line when targets were 
contoured around the original preoperative contrast-enhancing tumor plus a 2 cm 
margin. More than 80% of the recurrences occur in 2 cm of the surgical bed dose-
escalation studies analyzed 36 patients with HGGs treated with radiation alone to 
70–80 Gy using the 3D conformal techniques [22]. In this study, recurrences were 
divided into several categories: (1) “central,” in which 95% or more of the recurrent 
tumor volume (Vrecur) was within D95, the region treated to a high dose (95% of 
the prescription dose); (2) “infield,” in which 80% or more of V recur was within 
the D95 isodose surface; (3) “marginal,” when between 20 and 80% of Vrecur was 
inside the D95 surface; and (4) “outwith,” in which <20% of Vrecur was inside the 
D95 surface. This study found that 89% of the recurrences were central or infield, 
3/36 (8%) had a marginal recurrence pattern, and only one patient (3%) clearly 
failed outside of the high-dose region. Another trial [7] reported similar patterns 
of failure in a series of 48 patients with GBM, comparing treatment guidelines 
based on residual tumor and cavity plus 2 cm margin, as used at the MD Anderson 
Cancer Center, with RTOG guidelines that specified the inclusion of preoperative 
peritumoral edema. They showed that 90% (43/48) of patients failed in central 
and infield locations. The five remaining marginal and distal recurrences failed 
to be covered by the 46 Gy isodose line, even when overlaid by the RTOG plan 
incorporating edema volume, confirming them to be true marginal recurrences. 
Additionally, Minniti et al. [23] compared recurrence patterns in 105 patients whose 
surgical resections were delineated by the EORTC contouring technique, wherein 
the CTV includes the resection cavity, and any residual tumor seen on postopera-
tive T1-weighted MRI, plus a 2 cm margin, and the PTV includes the CTV plus an 
additional 3 mm margin. After recurrence was confirmed, a theoretical plan, based 
on the addition of postoperative edema plus 2 cm margins, according to the current 
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RTOG guidelines, was created for each patient. The radiation coverage of the site of 
subsequent recurrences was compared for the different contouring techniques. The 
results revealed no significant differences in relapse patterns between the two target 
delineation techniques. Although, the median percent volume of normal brain 
irradiated to high doses was significantly smaller using the EORTC guideline. In 
our opinion, these data provide some evidence and reassurance to support treat-
ment plans based on resection cavity and any residual tumor seen on postoperative 
T1-weighted MRI with a 2 cm margin, rather than specified inclusion of preopera-
tive peritumoral edema plus a 2 cm margin. The use of this limited-margin RT can 
significantly decrease the volume of normal brain tissue that is irradiated, without 
a significant increase in the risk of marginal recurrences. A number of studies 
have been conducted to explore the feasibility of limited-margin RT in the context 
of a treatment paradigm involving RT with concurrent chemotherapy. Trying to 
reduce treatment volume, McDonald et al. [8] report the pattern of tumor failure 
in a series of 62 patients with GBM treated with postoperative limited-margin 
RT and concurrent chemotherapy. The initial CTV included the postoperative 
T2 abnormality, with a median margin of 0.7 cm. The boost CTV included the 
residual T1-enhancing tumor and resection cavity, with a median margin of 0.5 cm. 
The PTV margin varied from an additional 0.3 cm–0.5 cm. The initial dose was 
46–54 Gy, followed by a boost to 60 Gy. In this study, the total boost PTV (PTVboost) 
margin was 1 cm or less in 92% of the patients. Results showed that 38/41 patients 
(93%) had a central or infield failure, two (5%) had a marginal failure, and one 
(2%) had a distant failure, relative to the 60 Gy isodose line. The author concluded 
that a PTVboost margin of 1 cm or less did not appear to increase the risk of marginal 
and/or distant tumor failure, compared with other published series. In the same 
direction, Dobelbower et al. [24] analyzed the patterns of failure in patients with 
GBM treated with concurrent radiation and TMZ. Patients generally received 46 Gy 
to the primary tumor, surrounding edema, plus a 1 cm margin and 60 Gy to the 
enhancing tumor plus a 1 cm margin. The result revealed that 18 patients (90%) 
had infield failures, 2 patients (10%) had marginal failures, and no regional failures 
were reported. Four patients (20%) suffered from distant failure, in which an 
independent satellite lesion was located completely outwith the 95% isodose curve. 
These studies also suggested that by delineating the GTV based on peritumoral 
edema, it is feasible to reduce the margin to 1 cm or less. Clinical studies showed 
that the volume of irradiated brain is important factor in the development of 
neurotoxicity and for the development of radiographic and pathologic surrogates 
for neurotoxicity [25–28].
Smaller RT fields may be more appropriate than larger RT fields, possibly 
reducing the risk of late neurological deterioration especially in patients with large 
peritumoral edema. The neurocognitive function would be likely to be affected by 
radiation therapy especially in long-term survivors [29].
The pattern of failure for GBM after radiation therapy has been studied previ-
ously; almost all tumors fail within a 2 cm margin of the resection cavity or residual 
tumor. The primary failure location was infield, but some patients had marginal 
failures, and few had a distant failure or an independent satellite lesion. Taking 
these data into consideration, we conclude that it is preferable to contour the GTV 
based on the T1-enhanced MRI, and regard the peritumoral edema as a subclini-
cal lesion. We suggest that the CTV should be identified based on the residual 
T1-enhancing tumor and resection cavity (GTV) with a 2 cm margin or the postop-
erative T2 or FLAIR (fluid-attenuated inversion recovery) abnormality; however, in 
the case of a cone-down boost phase, the CTV should include the GTV with a 1 cm 
margin.
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3. Dose
Standard therapy for HGG patients is a total dose of 60 Gy in 30–33 fractions 
[30]. Adequate doses of RT are required to maximize the survival benefit [31–33]. 
One important study conducted by Walker et al. evaluated the relationship between 
survival and increasing doses of RT in malign gliomas [33]. Doses ranged from <45 Gy 
to 60 Gy. They showed that there was a significant improvement in median survival 
from 28 to 42 weeks in the groups treated with doses of 50–60 Gy. There is no benefit 
for dose escalation of >60 Gy. In two randomized trials, there were no significant dif-
ferences in tumor control or survival in patients treated with 60 Gy cranial radiation 
or 60 Gy followed by a 10 Gy tumor boost [34, 35]. Two series [35, 36] analyzed failure 
patterns for patients with HGG dose escalation levels 70, 80, and 90 Gy. The GTV 
was defined based on postoperative gadolinium-enhanced T1-weighted images. They 
defined three separate PTVs in three dimensions by 0.5 cm to make PTV1, 1.5 cm to 
make PTV2, and 2.5 cm to make PTV3 from GTV. At median follow-up of 11.7 months, 
median survival was found to be 11.7 months, and 1- and 2-year survivals were 47.1% 
and 12.9%, respectively. The authors concluded that despite dose escalation to 90 Gy, 
the predominant failure pattern in HGG remained local. This suggested that close 
margins used in highly conformal treatments did not increase the risk of marginal 
or distant recurrences. Since the majority of tumor recurrences were seen within the 
previous radiation therapy fields and the poor outcomes associated with standard regi-
men, the new therapy strategies were evaluated to deliver higher doses to the tumor 
bed. Higher doses for HGG have been attempted with a variety of methods, including 
altered fractionation [37, 38], stereotactic radio surgery [39], and brachytherapy [40].
The term “conventional RT” refers to giving daily radiation of 180–200 cGy per day. 
“Hypofractionated RT” refers to the use of a higher daily dose of radiation (> 200 cGy 
per day) which typically reduces the overall number of fractions and therefore the 
overall treatment time. “Hyperfractionated RT” defined as the use of a lower daily dose 
of radiation (< 180 cGy per day), a greater number of fractions and multiple fractions 
delivered per day in order to deliver a total dose at least equivalent to external beam 
daily conventionally fractionated RT in the same time frame. The aim of this approach 
is to reduce the potential for late toxicity [41, 42]. In this study, the authors compared 
hyperfractionated RT (with or without chemotherapy) vs. conventionally fraction-
ated RT (without chemotherapy). The trial included 81 HGG patients randomized 
to conventional fractionation (5800 cGy in 30 daily fractions) or hyperfractionation 
(6141 cGy in 89 cGy fractions given 3 times a day every 2–4 hours for 4.5 weeks). 
Median survival in two groups was 39 and 27 weeks, respectively, and the 1-year sur-
vival rates were 41 and 20%, respectively. Others have failed to confirm these results. 
Therefore, there is insufficient data regarding hyperfractionation vs. conventionally 
fractionated radiation (without chemotherapy) and insufficient data regarding acceler-
ated radiation vs. conventionally fractionated radiation (without chemotherapy) [43].
“Hypofractionated RT” refers to the delivery of higher daily dose to reduce the 
overall treatment time. Five studies that randomized participants to hypofrac-
tionated radiation therapy vs. conventionally fractionated RT [43]. Their results 
suggested that hypofractionated RT has similar efficacy for survival as compared 
to conventional radiotherapy, especially for individuals aged 60 and older with 
HGG. A randomized controlled trial (RCT) and several retrospective studies 
conducted in the elderly suggest that short course-radiation therapy (SCRT) of 
34–40 Gy in 2.6–3.4 Gy fractions, with or without TMZ, may have similar results to 
LCRT [44–46]. Results from the Nordic trial suggested that SCRT may be superior 
to LCRT in patients aged ≥70 years [47]. An International Atomic Energy Agency 
Randomized Phase III Study of Radiation Therapy in Elderly and/or Frail Patients 
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with Newly Diagnosed Glioblastoma Multiforme showed no differences in overall 
survival time, progression-free survival time, and quality of life between patients 
receiving the two radiotherapy regimens (25 Gy in five daily fractions over 1 week 
vs. 40 Gy in 15 daily fractions over 3 weeks) [48].
There are no data comparing optimal dose and schedule in grade III gliomas vs. 
GBM. However, many radiation oncologists use a dose of 59.4 Gy in 1.8 Gy frac-
tions for grade III tumors vs. 60 Gy in 2 Gy fractions for grade IV tumors with the 
expectation that dose reduction per fraction may lead to reduced late normal tissue 
effects for patients with probability longer-term survival [49].
4. Stereotactic radiotherapy and radiosurgery (SRS)
Stereotactic radiotherapy or radiosurgery (SRS) uses three-dimensional plan-
ning techniques to precisely deliver narrowly collimated beams of ionizing radiation 
in a single high-dose fraction to small lesions [50, 51]. This technique in primary 
treatment of HGG was used in some trials a boost (additional dose). The treatment 
was composed of 50 Gy conventional RT and four SRT boost fractions of either 5 
or 7 Gy. SRT was administered once weekly during the final 4 weeks of therapy. 
The results suggested that while the regimen was safe, there was no survival benefit 
compared to the standard of care. Some retrospective studies suggest that it may 
be used in patients with recurrent HGG previously irradiated. A number of small 
prospective and retrospective series suggest that SRS may prolong survival in this 
setting, either alone or in combination with chemotherapy [52]. It is important to 
know the bias of these studies including the initial radiation dose, extent of initial 
and second surgical resections, tumor volume at the time of SRS, and timing and 
use of chemotherapy and the time between initial radiation therapy and retreat-
ment have clear implications on patient outcomes but are variably reported  
[52, 53]. Patients newly diagnosed with progressive/recurrent gliomas, there is 
insufficient evidence in terms of the benefits/harms of using SRS/SRT. There is also 
insufficient evidence regarding the benefits/harms in the use of SRS/SRT at the 
time of progression or recurrence.
5. Reirradiation in recurrent high-grade gliomas
Tumor recurrence is inevitable in HGG patients, but diagnostic of progressive 
disease from radiation necrosis or other radiation-induced imaging changes could be 
a big challenge. Treatment decisions for patients with recurrent or progressive HGG 
must be individualized, since therapy is not curative and there are no randomized 
trials that directly compare active intervention vs. supportive care. Reoperation is an 
important treatment modality and may involve either biopsy (for diagnostic pur-
poses) or repeat debulking of tumor, but only 20–30% of recurrent HGG patients are 
candidates for another surgery [54]. Focal RT approaches are often employed with 
limited volume recurrences; however, the role of reirradiation in patients with recur-
rent HGG is uncertain, and there is a lack of prospective data. Based on retrospective 
series, selected patients with small recurrent tumors and a good performance status 
may benefit from repeat radiation using modern high-precision techniques [55]. In a 
small series of 101 patients with recurrent HGG, the median survival was 12 months 
for patients with grade III tumors and 8 months for those with grade IV lesions. In 
this study SBRT was performed with a median dose of 36 Gy (range 15–62) [56].
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6. Toxicity of radiotherapy
The toxicity of RT usually divided into acute and late effects, effects dif-
ferentiated by time that occur, during radiation or up to 3 months afterward, 
early-delayed effects that appear up to 6 months after radiation, and late effects 
that can develop 6 months or more after the completion of radiation. Usually, 
acute reactions are reversible, and late reactions are generally irreversible. Most 
common acute radiation morbidity during cranial irradiation includes fatigue, 
erythema, alopecia, headache, and nausea with or without vomiting; these are 
usually not severe and are self-limiting [49]. The factors influencing the likeli-
hood of developing complications include the volume of normal brain tissue 
treated and the total radiation dose. Fatigue is one of the most common side 
effects of cranial irradiation. In a prospective study with 70 consecutive patients 
receiving radical cranial irradiation, most of the patients were treated for GBM, 
and their results suggested that 90% of the patients experienced ≥ grade 1 
symptoms (disturbance with some tiredness, but activity not curtailed), and 
approximately half experienced mild to moderate symptoms like decreased activ-
ity and increased tiredness, sleeping much of the day or most activities curtailed. 
The symptoms typically began within 2 weeks of the start of RT, peaked at 
approximately 6–8 weeks, and then slowly resolved over the next several months. 
Corticosteroids or antiemetic are used to prevent or abbreviate the symptoms. 
Late effects including cognitive impairments and radiation necrosis are worri-
some and may become manifest many years after RT [57]. Cranial irradiation can 
result in a spectrum of neurocognitive deficits in the years following treatment 
in children and in adults. The data of radiation-induced cognitive impairment 
is mostly learned from studies that are conducted in low-grade glioma patients. 
Cognitive functioning in patients with brain tumor was affected by the antiepi-
leptic drug use, extent of surgery, tumor localization, and age [57]. Radiation 
necrosis is a serious and uncommon late toxicity that typically develops 1–3 years 
after radiation, but in rare cases it has been reported more than 10 years after 
radiation [58]. The probability of radiation necrosis is strict dependence on the 
dose. Focal brain radiation with doses around 70 Gy using conventional 2 Gy 
fractionation risk of focal radiation necrosis is usually estimated in 5% in 5 years 
[59]. The risk of radiation necrosis probably increases with concurrent chemo-
therapy or radio sensitizers [60].
7. Conclusion
The standard of care for HGG adults, up to age 70 with good performance 
status, is conformal fractionated radiotherapy (6000 cGy in 30 daily fractions) with 
the addition of concurrent and adjuvant temozolomide chemotherapy following 
maximal safe debulking of the tumor. Elderly patients, older than 70 years or with 
poor performance status, hypofractionated RT has similar efficacy for survival as 
compared to conventional radiotherapy.
The optimal treatment volume for HGG patients remains controversial and var-
ies among cooperative groups; dose escalation above 60 Gy or stereotactic radio-
surgery has not shown any survival benefits. Treatment decisions for patients with 
recurrent or progressive HGG must be individualized, since therapy is not curative 
and there are no randomized trials that directly compare active intervention vs. 
supportive care.
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